With GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) facing fresh allegations of bribery, this time in Poland, Owain Bennallack focuses on those made in relation to Iraq and asks whether this newsflow ought to diminish the appeal of the company as a share…
https://youtu.be/8ZD3FVwHCwE